Celldex Therapeutics, Inc. $CLDX Shares Purchased by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 195.8% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 86,664 shares of the biopharmaceutical company’s stock after acquiring an additional 57,364 shares during the period. Seven Fleet Capital Management LP’s holdings in Celldex Therapeutics were worth $3,225,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Celldex Therapeutics during the third quarter worth $42,000. Nykredit A S acquired a new position in Celldex Therapeutics in the second quarter valued at $67,000. Russell Investments Group Ltd. lifted its position in Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares during the period. Quantbot Technologies LP purchased a new position in Celldex Therapeutics during the third quarter worth about $63,000. Finally, Kestra Advisory Services LLC purchased a new position in Celldex Therapeutics during the fourth quarter worth about $98,000.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Wall Street Zen upgraded Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Wells Fargo & Company increased their price objective on shares of Celldex Therapeutics from $48.00 to $72.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Cantor Fitzgerald decreased their target price on shares of Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Friday, July 17th. Finally, Morgan Stanley boosted their target price on shares of Celldex Therapeutics from $40.00 to $46.00 and gave the company an “overweight” rating in a report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Celldex Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $56.08.

Celldex Therapeutics Trading Down 1.6%

Shares of Celldex Therapeutics stock opened at $40.57 on Thursday. Celldex Therapeutics, Inc. has a twelve month low of $21.40 and a twelve month high of $45.14. The stock has a market capitalization of $3.19 billion, a P/E ratio of -9.33 and a beta of 0.87. The business’s fifty day moving average price is $38.22 and its 200 day moving average price is $33.11.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.12. The firm had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.73 million. As a group, sell-side analysts predict that Celldex Therapeutics, Inc. will post -4.13 EPS for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.